Silence Therapeutics plc (SLNCF) Stock Price & Analysis
Silence Therapeutics plc (SLNCF) — price $6.53 (0.00%), as of the Nov 19, 2026 trading session; market cap $1.22B.
Educational signal · not a buy or sell recommendation · How to read this
Silence Therapeutics plc · SLNCF
Silence Therapeutics plc is a biotechnology company focused on developing novel RNA therapeutics. Their mRNAi GOLD platform targets disease-associated genes in hematology, cardiovascular, and metabolic indications.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $6.53 | |
| Change on the day | 0.00% | |
| 52-week range | $1.06 – $6.53 | |
| Market capitalisation | $1.22B | — |
| Shares traded on the day | 51.8K |
Price & events
Other perspectives
Council score for Silence Therapeutics (SLNCF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Silence Therapeutics (SLNCF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Silence Therapeutics plc (SLNCF) is the company analyzed here. It employs 88 people and is led by Iain Gladstone Ross. In Q1 FY2026 it reported revenue of $421,292 and net income of -$15M. The market values it at $1.22B.
What do the latest results show for Silence Therapeutics (SLNCF)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $421,292. Against analyst estimates the company has EPS beat 2 of the last 8 reports.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $421,292 | -$15M | -$0.96 (diluted) |
| Q4 FY2025 | $34,000 | -$12M | -$0.75 (diluted) |
What are the financial strengths and risks for Silence Therapeutics (SLNCF)?
Short answer · as of
The distress and quality screens read Altman Z -2.42 · Piotroski F 1. Trailing ratios: ROE -56.3% · ROA -18.3% · current ratio 23.94 · earnings yield -4.7% · free-cash-flow yield -4.7%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -2.42 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-56.3%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SLNCF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SLNCF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: SLNCF Stock
These answers are editorial: 1 of these 8 answers is drawn from the SLNCF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is SLNCF a good stock to buy?
Stock Expert AI does not rate SLNCF buy, sell or hold. Silence Therapeutics plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the SLNCF stock price today?
The last price recorded for Silence Therapeutics plc (SLNCF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about SLNCF stock?
Analyst coverage of SLNCF stock is limited due to its OTC listing and relatively small market capitalization. However, analysts generally view Silence Therapeutics' RNA therapeutic platform and clinical pipeline as promising.
What are the key factors to evaluate for SLNCF?
Evaluate SLNCF on fundamentals, analyst consensus, and risk factors. Collaboration agreements with AstraZeneca, Mallinckrodt, and Hansoh Pharmaceutical provide financial support and validation of the company's technology. Not financial advice.
How frequently does SLNCF data refresh on this page?
SLNCF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven SLNCF's recent stock price performance?
Silence Therapeutics plc (SLNCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary mRNAi GOLD platform for targeted RNA interference. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SLNCF overvalued or undervalued right now?
Silence Therapeutics plc (SLNCF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SLNCF before investing?
Before investing in Silence Therapeutics plc (SLNCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com